vCJD caution prompts Serono product withdrawal

pharmafile | October 24, 2003 | News story | |   

Serono is to withdraw one of its hormone products from the UK after a case of variant Creutzfeldt-Jakob disease was confirmed in Italy, where the product is manufactured.

The Committee on Safety of Medicines advised the withdrawal of IVF treatment Metrodin High Purity only as a precautionary measure, and stressed no cases of vCJD transmitted via urine or urine products have been reported.

The CSM added that there are adequate supplies of alternative products and that other urine-derived products on the UK market are unaffected.

The move follows the Government's recent purchase of a US company to guarantee supplies of blood plasma free of vCJD.

The NHS no longer uses plasma from British blood donors because they have, in theory, been exposed to vCJD through the food chain.

Related Content

No items found

Latest content